Pharmacological approaches to smoking cessation

Pulmonary Pharmacology and Therapeutics

Volumn 20, Issue 3, 2007, Pages 220-232

  Mitrouska, I ^a   Bouloukaki, I ^a   Siafakas, N M ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Nicotine addiction; Smoking cessation; Smoking pharmacotherapy

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANXIOLYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUSPIRONE; CANNABINOID RECEPTOR ANTAGONIST; CLONIDINE; DIAZEPAM; DOXEPIN; DRUG METABOLITE; ERYTHROHYDROBUPROPION; HYDROXYBUPROPION; IMIPRAMINE; MECAMYLAMINE; MEPROBAMATE; MOCLOBEMIDE; NALOXONE; NALTREXONE; NICOTINE; NICOTINE GUM; NICOTINE PATCH; NORTRIPTYLINE; OPIATE ANTAGONIST; RIMONABANT; THEOHYDROBUPROPION; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARENICLINE;

ABDOMINAL PAIN; AGITATION; ARTICLE; BEHAVIOR THERAPY; BONE PAIN; CLINICAL ASSESSMENT; COMBINATION CHEMOTHERAPY; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; COUGHING; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DYSPEPSIA; FOLLOW UP; GENETIC SUSCEPTIBILITY; HEALTH CARE COST; HEART PALPITATION; HUMAN; HYPERTENSION; HYPOTENSION; INCIDENCE; INSOMNIA; LIVER NECROSIS; LOZENGE; MONOTHERAPY; MOUTH LESION; NAUSEA; NEUROBIOLOGY; NICOTINE REPLACEMENT THERAPY; NOSE IRRITATION; PATIENT COUNSELING; PRIORITY JOURNAL; PRURITUS; PSYCHOPHARMACOTHERAPY; QUALITY OF LIFE; RASH; RECOMMENDED DRUG DOSE; RHINORRHEA; SEDATION; SEIZURE; SIDE EFFECT; SINUSITIS; SMOKING CESSATION; SUSTAINED DRUG RELEASE; THROAT IRRITATION; TOBACCO DEPENDENCE; TREATMENT OUTCOME; WITHDRAWAL SYNDROME; XEROSTOMIA;

BUPROPION; DOPAMINE UPTAKE INHIBITORS; DRUG THERAPY; HUMANS; MODELS, PSYCHOLOGICAL; NICOTINE; NICOTINIC AGONISTS; SMOKING CESSATION; TOBACCO USE DISORDER;

EID: 33846913229     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2005.10.012     Document Type: Article

References (143)

1. Russell M.A. Cigarette smoking: natural history of a dependence disorder. Br J Med Psychol 44 1 (1971)
2. Department of Health. Smoking kills: a white paper on tobacco: London UK Government Report (1998), The Stationery Office, London
3. World Health Organization. Tobacco or health: a global status report (1997), World Health Organization, Geneva
4. World Health Organization. The European report on tobacco control policy. WHO European Ministerial Conference for a Tobacco-Free Europe (2002), World Health Organization, Warsaw (February 18-19)
5. Anthonisen N.R., et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 142 4 (2005) 233-239
6. Russell M.A.H. Tobacco dependence: is nicotine rewarding or aversive?. In: Krasnegor N.A. (Ed). Cigarette smoking as a dependence process. National Institute on Drug Abuse Research Monograph vol. 23 (1979), US Government Printing Office, Washington, DC 100-122
7. Jarvis M.J. Why people smoke. BMJ 328 7434 (2004) 277-279
8. Picciotto M.R. Nicotine as a modulator of behavior: beyond the inverted U. Trends Pharmacol Sci 24 9 (2003) 493-499
9. Benowitz N.L., and Henningfield J.E. Establishing a nicotine threshold for addiction. The implications for tobacco regulation. N Engl J Med 331 2 (1994) 123-125
10. Benowitz N.L. Pharmacology of nicotine: addiction and therapeutics. Annu Rev Pharmacol Toxicol 36 (1996) 597-613
11. Benowitz N.L. Nicotine addiction. Prim Care 26 3 (1999) 611-631
12. Silagy C., et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 4 (2002) CD000146
13. The Agency for health care policy and research smoking cessation clinical practice guideline. JAMA 275 16 (1996) 1270-1280
14. Manley M., et al. Clinical interventions in tobacco control. A National Cancer Institute training program for physicians. JAMA 266 22 (1991) 3172-3173
15. Fiore M.C. Treating tobacco use and dependence: an introduction to the US public health service clinical practice guideline. Respir Care 45 10 (2000) 1196-1199
16. Rigotti N.A. Clinical practice. Treatment of tobacco use and dependence. N Engl J Med 346 7 (2002) 506-512
17. National Institute for Clinical Excellence. Guidance on the use of nicotine replacement therapy (NRT) and bupropion for smoking cessation. Technology Appraisal Guidance No. 39, National Institute for Clinical Excellence, 2002.
18. Fiore M.C., Jorenby D.E., and Baker T.B. Smoking cessation: principles and practice based upon the AHCPR Guideline, 1996. Agency for health care policy and research. Ann Behav Med 19 3 (1997) 213-219
19. Royal College of Physicians. Nicotine addiction in Britain: A Report of Tobacco Advisory Group of the Royal College of Physicians (2000), Royal College of Physicians, London
20. Dani J.A., and De Biasi M. Cellular mechanisms of nicotine addiction. Pharmacol Biochem Behav 70 4 (2001) 439-446
21. Picciotto M.R., et al. Nicotinic receptors in the brain. Links between molecular biology and behavior. Neuropsychopharmacology 22 5 (2000) 451-465
22. Wooltorton J.R., et al. Differential desensitization and distribution of nicotinic acetylcholine receptor subtypes in midbrain dopamine areas. J Neurosci 23 8 (2003) 3176-3185
23. Benwell M.E., and Balfour D.J. Effects of chronic nicotine administration on the response and adaptation to stress. Psychopharmacology (Berlin) 76 2 (1982) 160-162
24. Epping-Jordan M.P., et al. Dramatic decreases in brain reward function during nicotine withdrawal. Nature 393 6680 (1998) 76-79
25. Marks M.J., Burch J.B., and Collins A.C. Effects of chronic nicotine infusion on tolerance development and nicotinic receptors. J Pharmacol Exp Ther 226 3 (1983) 817-825
26. Schwartz R.D., and Kellar K.J. Nicotinic cholinergic receptor binding sites in the brain: regulation in vivo. Science 220 4593 (1983) 214-216
27. Whiting P.J., and Lindstrom J.M. Characterization of bovine and human neuronal nicotinic acetylcholine receptors using monoclonal antibodies. J Neurosci 8 9 (1988) 3395-3404
28. Bergen A.W., and Caporaso N. Cigarette smoking. J Natl Cancer Inst 91 16 (1999) 1365-1375
29. Breese C.R., et al. Effect of smoking history on [3H]nicotine binding in human postmortem brain. J Pharmacol Exp Ther 282 1 (1997) 7-13
30. Peng X., et al. Nicotine-induced increase in neuronal nicotinic receptors results from a decrease in the rate of receptor turnover. Mol Pharmacol 46 3 (1994) 523-530
31. Marks M.J., et al. Nicotine binding and nicotinic receptor subunit RNA after chronic nicotine treatment. J Neurosci 12 7 (1992) 2765-2784
32. Feyerabend C., Ings R.M., and Russel M.A. Nicotine pharmacokinetics and its application to intake from smoking. Br J Clin Pharmacol 19 2 (1985) 239-247
33. Henningfield J.E., London E.D., and Benowitz N.L. Arterial-venous differences in plasma concentrations of nicotine after cigarette smoking. JAMA 263 15 (1990) 2049-2050
34. Marks M.J., Stitzel J.A., and Collins A.C. Dose-response analysis of nicotine tolerance and receptor changes in two inbred mouse strains. J Pharmacol Exp Ther 239 2 (1986) 358-364
35. Russell M.A., et al. Relation of nicotine yield of cigarettes to blood nicotine concentrations in smokers. Br Med J 280 6219 (1980) 972-976
36. Gries J.M., Benowitz N., and Verotta D. Chronopharmacokinetics of nicotine. Clin Pharmacol Ther 60 4 (1996) 385-395
37. Messina E.S., Tyndale R.F., and Sellers E.M. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J Pharmacol Exp Ther 282 3 (1997) 1608-1614
38. Rossing M.A. Genetic influences on smoking: candidate genes. Environ Health Perspect 106 5 (1998) 231-238
39. Straub R.E., et al. Susceptibility genes for nicotine dependence: a genome scan and followup in an independent sample suggest that regions on chromosomes 2, 4, 10, 16, 17 and 18 merit further study. Mol Psychiatry 4 2 (1999) 129-144
40. Boomsma D.I., et al. Genetic and social influences on starting to smoke: a study of Dutch adolescent twins and their parents. Addiction 89 2 (1994) 219-226
41. Carmelli D., et al. Genetic influence on smoking-a study of male twins. N Engl J Med 327 12 (1992) 829-833
42. Picciotto M.R., Brunzell D.H., and Caldarone B.J. Effect of nicotine and nicotinic receptors on anxiety and depression. Neuroreport 13 9 (2002) 1097-1106
43. American Psychiatric Association. Nicotine induced disorder: Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) (1995), APA, Washington
44. Hughes J.R., and Hatsukami D. Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry 43 3 (1986) 289-294
45. Fagerstrom K.O., Heatherton T.F., and Kozlowski L.T. Nicotine addiction and its assessment. Ear Nose Throat J 69 11 (1990) 763-765
46. Heatherton T.F., et al. The fagerstrom test for nicotine dependence: a revision of the Fagerstrom tolerance questionnaire. Br J Addict 86 9 (1991) 1119-1127
47. Woody G., et al. A review of the substance use disorders section of the DSM-IV. Psychiatr Clin North Am 16 1 (1993) 21-32
48. Folsom A.R., and Grimm Jr. R.H. Stop smoking advice by physicians: a feasible approach?. Am J Public Health 77 7 (1987) 849-850
49. Slama K., et al. The effectiveness of two smoking cessation programmes for use in general practice: a randomised clinical trial. BMJ 300 6741 (1990) 1707-1709
50. Silagy C., and Stead L.F. Physician advice for smoking cessation. Cochrane Database Syst Rev 2 (2001) CD000165
51. Simon J.A., et al. Intensive smoking cessation counseling versus minimal counseling among hospitalized smokers treated with transdermal nicotine replacement: a randomized trial. Am J Med 114 7 (2003) 555-562
52. Gritz E.R., Carr C.R., and Marcus A.C. The tobacco withdrawal syndrome in unaided quitters. Br J Addict 86 1 (1991) 57-69
53. Hughes J.R. Tobacco withdrawal in self-quitters. J Consult Clin Psychol 60 5 (1992) 689-697
54. Karnath B. Smoking cessation. Am J Med 112 5 (2002) 399-405
55. Fagerstrom K.O. A comparison of psychological and pharmacological treatment in smoking cessation. J Behav Med 5 3 (1982) 343-351
56. Lillington G.A., Leonard C.T., and Sachs D.P. Smoking cessation. Techniques and benefits. Clin Chest Med 21 1 (2000) 199-208 (xi)
57. Fiore M.C., et al. Tobacco dependence and the nicotine patch. Clinical guidelines for effective use. JAMA 268 19 (1992) 2687-2694
58. Hughes J., Stead L., and Lancaster L. Antidepressants for smoking cessation. Cochrane Database Syst Rev 4 (2004) CD000031
59. Gourlay S.G., Stead L.F., and Benowitz N.L. Clonidine for smoking cessation. Cochrane Database Syst Rev 3 (2004) CD000058
60. Alberg A.J., et al. Nicotine replacement therapy use among a cohort of smokers. J Addict Dis 24 1 (2005) 101-113
61. Hughes J.R. Pharmacotherapy for smoking cessation: unvalidated assumptions, anomalies, and suggestions for future research. J Consult Clin Psychol 61 5 (1993) 751-760
62. Lerman C., Patterson F., and Berrettini W. Treating tobacco dependence: state of the science and new directions. J Clin Oncol 23 2 (2005) 311-323
63. Henningfield J.E. Nicotine medications for smoking cessation. N Engl J Med 333 18 (1995) 1196-1203
64. Okuyemi K.S., Ahluwalia J.S., and Harris K.J. Pharmacotherapy of smoking cessation. Arch Fam Med 9 3 (2000) 270-281
65. Rennard S.I., and Daughton D.M. Smoking cessation. Chest 117 5 Suppl 2 (2000) 360S-364S
66. Marlow S.P., and Stoller J.K. Smoking cessation. Respir Care 48 12 (2003) 1238-1254 (discussion 1254-6)
67. Molyneux A. Nicotine replacement therapy. BMJ 328 7437 (2004) 454-456
68. Silagy C., et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 3 (2004) CD000146
69. Silagy C., et al. Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation. Lancet 343 8890 (1994) 139-142
70. West R., et al. A comparison of the abuse liability and dependence potential of nicotine patch, gum, spray and inhaler. Psychopharmacology (Berlin) 149 3 (2000) 198-202
71. Fiore M.C., et al. The effectiveness of the nicotine patch for smoking cessation. A meta-analysis. JAMA 271 24 (1994) 1940-1947
72. Silagy C., et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 3 (2001) CD000146
73. Pomerleau O.F., et al. Prolonged nicotine patch use in quitters with past abstinence-induced depressed mood. J Substance Abuse Treat 24 1 (2003) 13-18
74. Imperial Cancer Research Fund General Practice Research Group. Randomised trial of nicotine patches in general practice: results at one year. BMJ 4 308 (1994) 1476-1477
75. Munafo M., et al. Are there sex differences in transdermal nicotine replacement therapy patch efficacy? A meta-analysis. Nicotine Tobacco Res 6 5 (2004) 769-776
76. Garvey A.J., et al. Effects of nicotine gum dose by level of nicotine dependence. Nicotine Tobacco Res 2 1 (2000) 53-63
77. Murray R.P., et al. Safety of nicotine polacrilex gum used by 3094 participants in the lung health study. Lung health study research group. Chest 109 2 (1996) 438-445
78. Anthonisen N.R., Connett J.E., and Murray R.P. Smoking and lung function of lung health study participants after 11 years. Am J Respir Crit Care Med 166 5 (2002) 675-679
79. Hjalmarson A., et al. The nicotine inhaler in smoking cessation. Arch Intern Med 157 15 (1997) 1721-1728
80. Schneider N.G., et al. Efficacy of a nicotine inhaler in smoking cessation: a double-blind, placebo-controlled trial. Addiction 91 9 (1996) 1293-1306
81. Simon J.A., et al. Bupropion for smoking cessation: a randomized trial. Arch Intern Med 164 16 (2004) 1797-1803
82. West R., et al. Individual differences in preferences for and responses to four nicotine replacement products. Psychopharmacology (Berlin) 153 2 (2001) 225-230
83. Sutherland G., et al. Nasal nicotine spray: a rapid nicotine delivery system. Psychopharmacology (Berlin) 108 4 (1992) 512-518
84. Sutherland G., et al. Randomised controlled trial of nasal nicotine spray in smoking cessation. Lancet 340 8815 (1992) 324-329
85. Hjalmarson A., et al. Effect of nicotine nasal spray on smoking cessation. A randomized, placebo-controlled, double-blind study. Arch Intern Med 154 22 (1994) 2567-2572
86. Choi J.H., et al. Pharmacokinetics of a nicotine polacrilex lozenge. Nicotine Tobacco Res 5 5 (2003) 635-644
87. Foulds J., et al. Nicotine absorption and dependence in unlicensed lozenges available over the counter. Addiction 93 9 (1998) 1427-1431
88. Shiffman S., et al. Efficacy of a nicotine lozenge for smoking cessation. Arch Intern Med 162 11 (2002) 1267-1276
89. Shiffman S., Dresler C.M., and Rohay J.M. Successful treatment with a nicotine lozenge of smokers with prior failure in pharmacological therapy. Addiction 99 1 (2004) 83-92
90. Hand S., et al. Controlled trial of three weeks nicotine replacement treatment in hospital patients also given advice and support. Thorax 57 8 (2002) 715-718
91. Blondal T., et al. Nicotine nasal spray with nicotine patch for smoking cessation: randomised trial with six year follow up. BMJ 318 7179 (1999) 285-288
92. Fiore M.C., Hatsukami D.K., and Baker T.B. Effective tobacco dependence treatment. JAMA 288 14 (2002) 1768-1771
93. Wagena E.J., et al. The efficacy of smoking cessation strategies in people with chronic obstructive pulmonary disease: results from a systematic review. Respir Med 98 9 (2004) 805-815
94. Ford C.L., and Zlabek J.A. Nicotine replacement therapy and cardiovascular disease. Mayo Clin Proc 80 5 (2005) 652-656
95. Hughes J.R., Stead L.F., and Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2 (2003) CD000031
96. Jorenby D.E., et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 340 9 (1999) 685-691
97. Ascher J.A., et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 56 9 (1995) 395-401
98. Hays J.T., and Ebbert J.O. Bupropion for the treatment of tobacco dependence: guidelines for balancing risks and benefits. CNS Drugs 17 2 (2003) 71-83
99. Hsyu P.H., et al. Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. J Clin Pharmacol 37 8 (1997) 737-743
100. Dunner D.L., et al. A prospective safety surveillance study for bupropion sustained-release in the treatment of depression. J Clin Psychiatry 59 7 (1998) 366-373
101. Johnston A.J., et al. Pharmacokinetic optimisation of sustained-release bupropion for smoking cessation. Drugs 62 Suppl 2 (2002) 11-24
102. Roddy E. Bupropion and other non-nicotine pharmacotherapies. BMJ 328 7438 (2004) 509-511
103. Settle Jr. E.C. Bupropion sustained release: side effect profile. J Clin Psychiatry 59 Suppl 4 (1998) 32-36
104. Hurt R.D., et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 337 17 (1997) 1195-1202
105. Jorenby D. Clinical efficacy of bupropion in the management of smoking cessation. Drugs 62 Suppl 2 (2002) 25-35
106. Robinson M.D., et al. Buspirone effect on tobacco withdrawal symptoms: a randomized placebo-controlled trial. J Am Board Fam Pract 5 1 (1992) 1-9
107. Cox L.S., et al. Efficacy of bupropion for relapse prevention in smokers with and without a past history of major depression. J Gen Intern Med 19 8 (2004) 828-834
108. Tonstad S., et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. Eur Heart J 24 10 (2003) 946-955
109. Tashkin D., et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 357 9268 (2001) 1571-1575
110. Collins B.N., et al. Gender differences in smoking cessation in a placebo-controlled trial of bupropion with behavioral counseling. Nicotine Tobacco Res 6 1 (2004) 27-37
111. Ahluwalia J.S., et al. Sustained-release bupropion for smoking cessation in African Americans: a randomized controlled trial. JAMA 288 4 (2002) 468-474
112. Dale L.C., et al. Bupropion for smoking cessation: predictors of successful outcome. Chest 119 5 (2001) 1357-1364
113. George T.P., and O'Malley S.S. Current pharmacological treatments for nicotine dependence. Trends Pharmacol Sci 25 1 (2004) 42-48
114. Killen J.D., et al. Randomized clinical trial of the efficacy of bupropion combined with nicotine patch in the treatment of adolescent smokers. J Consult Clin Psychol 72 4 (2004) 729-735
115. Hall S.M., et al. Extended nortriptyline and psychological treatment for cigarette smoking. Am J Psychiatry 161 11 (2004) 2100-2107
116. Rohsenow D.J., et al. Naltrexone treatment for alcoholics: effect on cigarette smoking rates. Nicotine Tobacco Res 5 2 (2003) 231-236
117. Lerman C., et al. Pharmacogenetic investigation of smoking cessation treatment. Pharmacogenetics 12 8 (2002) 627-634
118. Lancaster T., and Stead L.F. Mecamylamine (a nicotine antagonist) for smoking cessation. Cochrane Database Syst Rev 2 (2000) CD001009
119. Rose J.E., Behm F.M., and Westman E.C. Nicotine-mecamylamine treatment for smoking cessation: the role of pre-cessation therapy. Exp Clin Psychopharmacol 6 3 (1998) 331-343
120. Coe J.W., et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 48 10 (2005) 3474-3477
121. Foulds J., et al. Advances in pharmacotherapy for tobacco dependence. Expert Opin Emerg Drugs 9 1 (2004) 39-53
122. Black S.C. Cannabinoid receptor antagonists and obesity. Curr Opin Invest Drugs 5 4 (2004) 389-394
123. Henningfield J.E., et al. Pharmacotherapy for nicotine dependence. CA Cancer J Clin 55 5 (2005) 281-299 (quiz 322-3, 325)
124. Krishnan-Sarin S., Meandzija B., and O'Malley S. Naltrexone and nicotine patch smoking cessation: a preliminary study. Nicotine Tobacco Res 5 6 (2003) 851-857
125. Kuehn B.M. Could a novel vaccine help smokers quit?. JAMA 294 8 (2005) 891-892
126. Schroeder S.A. What to do with a patient who smokes. JAMA 294 4 (2005) 482-487
127. Clarke P.B. Nicotinic receptor blockade therapy and smoking cessation. Br J Addict 86 5 (1991) 501-505
128. Rose J.E., et al. Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clin Pharmacol Ther 56 1 (1994) 86-99
129. Cohen C., Kodas E., and Griebel G. CB1 receptor antagonists for the treatment of nicotine addiction. Pharmacol Biochem Behav 81 2 (2005) 387-395
130. Cohen C., et al. SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol 13 5-6 (2002) 451-463
131. Anthenelli RM. Smoking cessation in smokers motivated to quit. American College of Cardiology Scientific Sessions, 2004 March 7-10, New Orleans, LA.
132. Almeida L.E., et al. The opioid antagonist naltrexone inhibits activity and alters expression of alpha7 and alpha4beta2 nicotinic receptors in hippocampal neurons: implications for smoking cessation programs. Neuropharmacology 39 13 (2000) 2740-2755
133. Karras A., and Kane J.M. Naloxone reduces cigarette smoking. Life Sci 27 17 (1980) 1541-1545
134. Sutherland G., et al. Naltrexone, smoking behaviour and cigarette withdrawal. Psychopharmacology (Berlin) 120 4 (1995) 418-425
135. Pentel P.R., et al. A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacol Biochem Behav 65 1 (2000) 191-198
136. Malin D.H., et al. Passive immunization against nicotine prevents nicotine alleviation of nicotine abstinence syndrome. Pharmacol Biochem Behav 68 1 (2001) 87-92
137. Cerny T. Anti-nicotine vaccination: where are we?. Recent Results Cancer Res 166 (2005) 167-175
138. Hasman A., and Holm S. Nicotine conjugate vaccine: is there a right to a smoking future?. J Med Ethics 30 4 (2004) 344-345
139. Woolacott N.F., et al. The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation. Health Technol Assess 6 16 (2002) 1-245
140. Cornuz J., et al. Cost-effectiveness analysis of the first-line therapies for nicotine dependence. Eur J Clin Pharmacol 59 3 (2003) 201-206
141. Sutherland G. Smoking: can we really make a difference?. Heart 89 Suppl 2 (2003) ii25-iii7 (discussion ii35-7)
142. Gaspoz J.M., et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med 346 23 (2002) 1800-1806
143. Caro J., et al. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. BMJ 315 7122 (1997) 1577-1582